Sugi Predict

Sugi Predict / Compounds / SCHEMBL305165

SCHEMBL305165

SCHEMBL305165

Cc1ccc(C(N)=O)c(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.46
▸ DGAT1 O75907 1/20 0.46
▸ PARP1 P09874 1/20 0.44
▸ MAPT P10636 5/20 0.42
▸ NPC1 O15118 4/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ CSNK2A1 P68400 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ RIN1 Q13671 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MYC P01106 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ BTK Q06187 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13254950 0.83 MAPT (0.46) ERN1DGAT1PARP1MAPTNPC1
SCHEMBL27774516 0.83 MAPT (0.44) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL29775265 0.81 CSNK2A1 (0.55) NPC1SMN1; SMN2RAB9ACSNK2A1KMT2A
SCHEMBL12121788 0.81 NPC1 (0.41) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL1329346 0.81 CYP2A6 (0.42) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL211284 0.81 CSNK2A1 (0.55) NPC1SMN1; SMN2RAB9ACSNK2A1KMT2A
SCHEMBL31315013 0.79 RAB9A (0.41) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL7017242 0.79 RAB9A (0.41) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL6892362 0.79 ALDH1A1 (0.39) MAPTNPC1MAPK1HTTSMN1; SMN2
SCHEMBL11920159 0.79 ALDH1A1 (0.46) MAPTNPC1HTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 — — US disclosed
WO-2021000935-A1 HPK1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2021-01-07 — — WO disclosed
CN-106957273-B A kind of preparation method of quinazolinone and its derivative 大连理工大学 2019-06-07 — — CN disclosed
CN-109293585-A A method of halobenzamides rapid synthesis quinazolinones are utilized under microwave condition in water phase 云南师范大学 2019-02-01 — — CN disclosed
US-20170233352-A1 HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME MEMORIAL SLOAN KETTERING CANCER CENTER 2017-08-17 — — US disclosed
CN-106957273-A A kind of preparation method of quinazolinone and its derivative 大连理工大学 2017-07-18 — — CN disclosed
EP-1966166-B1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LTD (GB) 2013-01-23 — — EP disclosed
EP-1966166-B1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LTD (GB) 2013-01-23 — — EP disclosed
US-8093279-B2 Compound STERIX LIMITED (GB) 2012-01-10 — — US disclosed
US-8093279-B2 Compound STERIX LIMITED (GB) 2012-01-10 — — US disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 — — US disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 — — US disclosed
WO-2009100170-A1 DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS GLAXO GROUP LIMITED (GB) 2009-08-13 — — WO disclosed
US-20090197871-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-06 — — US disclosed
US-20090197871-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-06 — — US disclosed
US-20080319037-A1 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS STERIX LIMITED (GB) 2008-12-25 — — US disclosed
US-20080319037-A1 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS STERIX LIMITED (GB) 2008-12-25 — — US disclosed
EP-1966166-A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS Sterix Limited (GB) 2008-09-10 — — EP disclosed
WO-2007068905-A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LIMITED (GB) 2007-06-21 — — WO disclosed
WO-2007068905-A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LIMITED (GB) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4A, PDE4B, PDE1A ERN1 4259/4885DGAT1 1981/4885PARP1 3387/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 ERN1 376/4885DGAT1 2980/4885PARP1 1486/4885
US-20170233352-A1 HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME HSPA2, HSP90AA1, HSP90AB1 ERN1 2396/4885DGAT1 4807/4885PARP1 2956/4885
US-20080319037-A1 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS CYP19A1, CYP21A2, CBR1 ERN1 1606/4885DGAT1 3446/4885PARP1 3454/4885
US-20090197871-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4B, PDE4A, CHRM4 ERN1 4344/4885DGAT1 2501/4885PARP1 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.